Literature DB >> 8997595

Dysplastic nevi are a risk factor for uveal melanoma.

H Hammer1, J Oláh, E Tóth-Molnár.   

Abstract

Many studies have characterized the phenotypic features of individuals who are likely to develop cutaneous melanoma. One of the major items included in melanoma risk assessment has been the presence of clinically atypical nevi (dysplastic nevi). This study assessed the number of subjects with dysplastic nevi in groups of patients with uveal melanoma or cutaneous melanoma and in a group of volunteer controls. The SPSS program was used to calculate the odds ratios (hereafter called relative risks; RR) and 95% confidence intervals (C) in melanoma patients and controls. The RR was 4.36 for uveal melanoma (95% Cl 1.84-10.36) and 4.22 for cutaneous melanoma (95% Cl 1.81-9.84). These results suggest that cutaneous dysplastic nevi are a significant risk factor for uveal melanoma.

Entities:  

Mesh:

Year:  1996        PMID: 8997595     DOI: 10.1177/112067219600600423

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  11 in total

Review 1.  Uveal melanoma: relatively rare but deadly cancer.

Authors:  S Kaliki; C L Shields
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

Review 2.  Uveal melanoma: From diagnosis to treatment and the science in between.

Authors:  Chandrani Chattopadhyay; Dae Won Kim; Dan S Gombos; Junna Oba; Yong Qin; Michelle D Williams; Bita Esmaeli; Elizabeth A Grimm; Jennifer A Wargo; Scott E Woodman; Sapna P Patel
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

Review 3.  Evidence for the Role of Blue Light in the Development of Uveal Melanoma.

Authors:  Patrick Logan; Miguel Bernabeu; Alberto Ferreira; Miguel N Burnier
Journal:  J Ophthalmol       Date:  2015-05-17       Impact factor: 1.909

Review 4.  Treatment of uveal melanoma: where are we now?

Authors:  Jessica Yang; Daniel K Manson; Brian P Marr; Richard D Carvajal
Journal:  Ther Adv Med Oncol       Date:  2018-02-21       Impact factor: 8.168

5.  Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.

Authors:  Kristof Harda; Zsuzsanna Szabo; Erzsebet Szabo; Gabor Olah; Klara Fodor; Csaba Szasz; Gabor Mehes; Andrew V Schally; Gabor Halmos
Journal:  Molecules       Date:  2018-06-26       Impact factor: 4.411

6.  Current molecular and clinical insights into uveal melanoma (Review).

Authors:  Matteo Fallico; Giuseppina Raciti; Antonio Longo; Michele Reibaldi; Vincenza Bonfiglio; Andrea Russo; Rosario Caltabiano; Giuseppe Gattuso; Luca Falzone; Teresio Avitabile
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

Review 7.  Hypoxia-dependent drivers of melanoma progression.

Authors:  Simona D'Aguanno; Fabiana Mallone; Donatella Del Bufalo; Antonietta Moramarco; Marco Marenco
Journal:  J Exp Clin Cancer Res       Date:  2021-05-08

8.  Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.

Authors:  Prisca Bustamante; Thupten Tsering; Jacqueline Coblentz; Christina Mastromonaco; Mohamed Abdouh; Cristina Fonseca; Rita P Proença; Nadya Blanchard; Claude Laure Dugé; Rafaella Atherino Schmidt Andujar; Emma Youhnovska; Miguel N Burnier; Sonia A Callejo; Julia V Burnier
Journal:  J Exp Clin Cancer Res       Date:  2021-06-16

Review 9.  Metastatic disease from uveal melanoma: treatment options and future prospects.

Authors:  Richard D Carvajal; Gary K Schwartz; Tongalp Tezel; Brian Marr; Jasmine H Francis; Paul D Nathan
Journal:  Br J Ophthalmol       Date:  2016-08-29       Impact factor: 4.638

10.  Epidemiological Study of Uveal Melanoma from US Surveillance, Epidemiology, and End Results Program (2010-2015).

Authors:  Yufeng Xu; Lixia Lou; Yijie Wang; Qi Miao; Kai Jin; Menglu Chen; Juan Ye
Journal:  J Ophthalmol       Date:  2020-02-19       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.